263 RSV Hospitalization in Cystic Fibrosis in the Canadian Registry of Synagis® (Caress) following Prophylaxis (2005–2011). (October 2012)

• Record Type: Journal Article
• Authors: Paes, B; Li, A; Mitchell, I; Lanctot, KL
• Is Part Of: Archives of disease in childhood. Volume 97(2012)Supplement 2
• Page Start: A76
• Page End: A77
• Publication Date: 2012-10
• Subjects: Children -- Diseases -- Periodicals; Infants -- Diseases -- Periodicals; 618.920005
• DOI: 10.1136/archdischild-2012-302724.0263
• Languages: English
• ISSNs: 0003-9888

Abstract

Abstract : Background and Aims: The Canadian Registry of Synagis® (CARESS) tracks palivizumab utilization and respiratory syncytial virus (RSV) hospitalizations in high-risk infants including 186 with cystic fibrosis (CF). This study compares respiratory illness (RI) and RSV positive hospitalization (RSVH) rates in CF infants versus: those with other underlying medical disorders (MD) and those who meet standard indications for RSV prophylaxis (SD). Methods: A prospective, observational registry of infants from 30 sites who received ≥1 dose of palivizumab during the 2005–2011 RSV seasons. Palivizumab utilization and RI outcomes were collected monthly over each individual season. Results: 10, 452 infants were enrolled (CF: 186, 1.8%; MD: 1378, 13.2%; SD: 8888, 85.0%). There were significant differences (p<0.05) between the three groups in gestational and enrolment ages, weight at birth and at enrolment and proportions of: Caucasians, siblings, multiple births, daycare attendance, smokers in the household, >5 people in the household, immediate family history of atopy, and complexity of neonatal course. Infants with CF had a lower RI hospitalization rate than the MD (4.3% versus 11.0%, p=0.003) but not the SD group (5.8%, p=0.522). For RSVH rate, CF infants were not significantly different from the MD (0.72% versus 2.46%, p=0.227) or SD (1.49%, p=0.999) groups. In the Cox proportional analysis, hazard ratios of time to first RSVH in CF were similar to MD (p=0.272) and SD infants (p=0.422). Conclusions: This is the largest report of CF infants who have received palivizumab world-wide. Despite RI rate differences, RSVH rates appear similar to those in MD and SD.